Alkermes plc has been upgraded from Hold to Buy due to its robust revenue growth driven by the acquisition of Avadel and the launch of Lumryz, which are expected to propel over 20% revenue growth by 2026. The company projects adjusted EBITDA between $370–410 million despite a GAAP net loss. Strong Phase 2 data for Alixorexton in narcolepsy and idiopathic hypersomnia, along with advances in its orexin pipeline, support significant long-term revenue potential. Management changes and steady growth in core products further strengthen Alkermes' strategic position in sleep and central nervous system disorders, indicating a positive outlook.
SpaceX is expanding its AI infrastructure to support its rocket launches, Starlink satellite network, and future AI growth plans. Analysts show mixed but generally positive sentiment, with Morgan Stanley maintaining a Buy rating and a $300 price targ...
Byrna Technologies reported a fiscal Q3 loss of $0.13 per share, better than the expected $0.16 loss, but revenue fell 46% year-over-year to $15.3 million, missing estimates. The company shifted from net income to a $2.9 million net loss due to weake...
On October 8, 2026, several stocks including AngioDynamics, Apimeds Pharmaceuticals US, and Arqit Quantum experienced steep declines of over 18%, despite some positive financial reports. Leveraged ETFs CRWG and IRE also dropped 15.5%, highlighting th...
On October 8, 2026, Pacira BioSciences surged 44.4% following Viatris' agreement to acquire the company for $36.50 per share, valuing the deal at approximately $1.65 billion. Other notable gainers included Profound Medical, which rose 21.7% after for...
Glassnode data reveals that 4.33 million BTC, about 21.5% of circulating Bitcoin, is exposed due to address reuse, with total BTC behind visible public keys reaching 6.26 million BTC or 31.2% of supply. This exposure arises from both user behavior—re...
